This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: 02:01-restricted viral epitope NLVPMVATV (NLV-T cells) exhibit weakened immune control of HCMV reactivation. METHODS: Here, we characterised NLV-T cells from 116 healthy HCMV-positive donors, dividing them into two groups: those with low and those with high NLV-T cell frequencies (LF and HF, respectively). We phenotyped the cells using multi-colour spectral flow cytometry and single-cell RNA sequencing coupled with TCR profiling and examined their killing properties against peptide-loaded and virus-infected target cells. FINDINGS: Our comprehensive multimodal analysis revealed that NLV-T cells from HF donors exhibited a phenotype of advanced differentiation, marked by high levels of granzyme B and perforin expression, and efficiently eliminated peptide-loaded targets and HCMV-infected cells as long as cell surface HLA expression was unaffected. However, NLV-T cells from LF donors, possessing a less differentiated granzyme K-intermediate phenotype, demonstrated enhanced cytokine secretion and the ability to eliminate HCMV-infected cells, even in the presence of virus-induced HLA class-I downregulation. INTERPRETATION: Overall, these findings suggest that HCMV exploits CD8 T cell differentiation to evade immune protection. These data are crucial for understanding the previously observed decline in HCMV reactivation control in individuals with NLV-T cell accumulation. Moreover, our findings have clinical implications and could guide future research on adoptive T-cell therapy, and the potential use of HCMV as a vaccine vector.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fritz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: